Understanding The Manufacturing Responsibilities Of Drug Substances And Drug Products

Navigating biologics manufacturing requires clarity around the responsibilities and risks associated with both drug substance and drug product production. Drug substance work—spanning cell line or strain development, upstream processing, purification, and analytical characterization—must be designed for scalability and regulatory compliance. Drug product manufacturing then transforms the purified active ingredient into its final form through formulation, sterile processing, fill‑finish operations, and stability testing. Each stage carries unique technical demands, and failing to plan for scale, regulatory expectations, or technology transfer can lead to costly setbacks. Additionally, even when outsourcing manufacturing activities, the sponsoring organization remains accountable for overall product quality, regulatory oversight, and documentation review. Early engagement with experienced partners helps identify scalability issues, streamline development, and reduce risk during the transition to GMP manufacturing. By understanding and planning for these responsibilities early, organizations can better align timelines, strengthen regulatory readiness, and accelerate progress toward clinical production.